Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer

DISEASE CHARACTERISTICS: * Cytologically or histologically confirmed breast cancer * Metastatic OR locally recurrent disease * Unresectable disease * Not amenable to radiotherapy * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan * Measurable disease must be outside irradiated areas * ErbB2-negative disease by immunohistochemistry (negative or 1+) or fluorescent in situ hybridization (FISH) * No known CNS metastases, even if previously treated * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Female * Menopausal status not specified * WHO performance status 0-1 * LVEF ≥ 55% * Hemoglobin ≥ 10.0 g/dL * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Bilirubin \< 2 times upper limit of normal (ULN) * ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present) * Alkaline phosphatase (AP) ≤ 2.5 times ULN * AP \> 2.5 times ULN and ≤ 6 times ULN allowed if ALT ≤ 1.5 times ULN * AP \> 6 times ULN allowed if ALT normal * Creatinine ≤ 1.5 times ULN * Proteinuria \< 2+ by dipstick OR protein ≤ 1 g/24hr-urine collection * INR ≤ 1.5 OR Quick ≥ 70% * aPTT ≤ 1.5 times ULN * No peripheral neuropathy \> grade 2 * No history or evidence of hereditary bleeding diathesis or coagulopathy with the risk of bleeding * No uncontrolled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg and/or diastolic BP \> 100 mm Hg, measured repeatedly at \> 2 visits despite adequate treatment with ≥ 2 different antihypertensive drugs * No clinically significant cardiovascular disease, including the following: * Cerebrovascular accident or stroke within the past 6 months * Myocardial infarction within the past 6 months * Unstable angina * New York Heart Association class II-IV congestive heart failure * Serious cardiac arrhythmia (e.g., ventricular arrhythmia, high-grade atrioventricular-block) not controlled by medication or requiring medication which might interfere with regularity of the study treatment * No serious nonhealing wound, active peptic ulcer, nonhealing bone fracture, or bleeding skin metastases * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No active infection requiring IV antibiotics * No known hypersensitivity to any of the study drugs or excipients * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies * No evidence of any other disease that contraindicates the use of an investigational drug, that may affect patient compliance with study routines, or places the patient at high risk for treatment-related complications including, but not limited to, the following: * Metabolic dysfunction * Physical examination finding * Psychological dysfunction * Clinical laboratory finding giving reasonable suspicion of a disease or condition * No known CNS disease unrelated to cancer (e.g., uncontrolled seizures), unless adequately treated with standard medical therapy * No high-risk factors for bleeding, including the following: * Coagulation parameters outside range * Need for concurrent anticoagulant therapy * Insufficient time gap after surgical procedures * No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * No significant traumatic injury within the past 28 days * No known HIV positivity * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 12 months after completion of study therapy PRIOR CONCURRENT THERAPY: * No prior chemotherapy for metastatic or inoperable locally recurrent breast cancer * No prior bevacizumab or other anti-vascular endothelial growth factor drug therapy * No prior radiotherapy involving the heart (usual irradiation dose to breast or chest wall allowed) * More than 12 months since prior neoadjuvant or adjuvant chemotherapy * No neoadjuvant or adjuvant doxorubicin hydrochloride with cumulative dose \> 360 mg/m² or epirubicin hydrochloride with cumulative dose \> 720 mg/m² * More than 6 months since prior adjuvant radiotherapy * More than 28 days since prior major surgical procedure with high risk of bleeding * More than 24 hours since prior minor surgical procedures * More than 10 days since prior acetylsalicylic acid (\> 325 mg/day) or clopidogrel bisulfate (\> 75 mg/day) * More than 10 days since prior and no concurrent use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes * Prophylactic use of anticoagulants allowed (e.g., for maintenance of venous catheter) * More than 30 days since prior investigational therapies or participation in other investigational studies * No concurrent hormonal therapy * No other concurrent antineoplastic or antitumor therapy * No other concurrent investigational drugs * No concurrent radiotherapy * No concurrent nonsteroidal anti-inflammatory drugs with activity on platelets and gastric mucosa (e.g., dipyridamole, clopidogrel bisulfate, acetylsalicylic acid) * No anticipated need for major surgery during the course of the study treatment